Avanos Medical Files 8-K
Ticker: AVNS · Form: 8-K · Filed: Sep 15, 2025 · CIK: 1606498
| Field | Detail |
|---|---|
| Company | Avanos Medical, INC. (AVNS) |
| Form Type | 8-K |
| Filed Date | Sep 15, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, financials
Related Tickers: AVNS
TL;DR
AVNS filed an 8-K on 9/15/25. Check for Reg FD and financial updates.
AI Summary
Avanos Medical, Inc. filed an 8-K on September 15, 2025, reporting on Regulation FD disclosures and financial statements. The company, formerly known as Halyard Health, Inc., is based in Alpharetta, Georgia.
Why It Matters
This filing provides important updates and disclosures for investors regarding Avanos Medical's financial status and regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K report, which typically contains standard disclosures and financial information.
Key Players & Entities
- AVANOS MEDICAL, INC. (company) — Registrant
- September 15, 2025 (date) — Date of earliest event reported
- Halyard Health, Inc. (company) — Former company name
- Alpharetta, Georgia (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Avanos Medical, Inc.?
The filing is for a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically covering Regulation FD Disclosure and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported was on September 15, 2025.
What is the exact name of the company filing this report?
The exact name of the registrant is AVANOS MEDICAL, INC.
What was Avanos Medical, Inc. formerly known as?
Avanos Medical, Inc. was formerly known as Halyard Health, Inc.
Where are Avanos Medical, Inc.'s principal executive offices located?
The principal executive offices are located at 5405 Windward Parkway, Suite 100 South, Alpharetta, Georgia 30004.
Filing Stats: 524 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-09-15 07:05:08
Key Financial Figures
- $0.01 — nge on which registered Common Stock - $0.01 Par Value AVNS New York Stock Exchange
Filing Documents
- avns-20250915.htm (8-K) — 27KB
- avnsform8k_09152025xex991.htm (EX-99.1) — 9KB
- avns-20250915_g1.jpg (GRAPHIC) — 15KB
- 0001606498-25-000123.txt ( ) — 195KB
- avns-20250915.xsd (EX-101.SCH) — 2KB
- avns-20250915_lab.xml (EX-101.LAB) — 22KB
- avns-20250915_pre.xml (EX-101.PRE) — 13KB
- avns-20250915_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On September 15, 2025, Avanos Medical, Inc. (the "Company") issued a press release announcing that the Company has acquired Nexus Medical, LLC. A copy of such press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein in its entirety. The information in Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in Item 7.01 of this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as otherwise expressly stated in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits. The following exhibits are filed with this Current Report on Form 8-K: Exhibit No. Description 99.1 Press release issued by Avanos Medical, Inc. on September 15, 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVANOS MEDICAL, INC. Date: September 15, 2025 By: /s/ Mojirade James Mojirade James Senior Vice President and General Counsel